HeartBeam has enrolled the first patients in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The enrollment marks a key step toward generating clinical data needed to expand the system's indication beyond arrhythmia assessment to include heart attack detection. The first patients were enrolled by Prof. Dr. Vladan Vukcevic at the University Clinical Center of Serbia in Belgrade. This pilot study represents a significant advancement for the medical technology company's platform, which aims to transform cardiac care by providing powerful cardiac insights outside traditional medical settings.
HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians could potentially identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to technology enablement. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.
This development could redefine the future of cardiac health management by enabling earlier detection of heart attacks through portable technology. The ability to detect heart attacks outside medical facilities represents a potential paradigm shift in cardiac care, particularly for patients who may not immediately recognize symptoms or have access to emergency medical services. The ALIGN-ACS study represents the next phase in HeartBeam's development of its cardiac monitoring platform. If successful, the technology could provide a new tool for physicians to monitor patients with cardiac risk factors and potentially intervene earlier in acute cardiac events. The company's forward-looking statements note that actual results may differ from expectations due to various factors beyond management's control. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer. The technology's expansion into heart attack detection represents a significant step toward making comprehensive cardiac assessment more accessible and portable for patients worldwide.
